Article Details
Retrieved on: 2024-11-08 21:19:51
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Entera Bio reported Q3 2024 financial results and updates on its oral peptide development programs. The company's lead asset, EB613, is advancing ...
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here